Working... Menu

Effect of Aging on Haemostasis Parameters

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00299624
Recruitment Status : Completed
First Posted : March 7, 2006
Last Update Posted : September 14, 2010
Information provided by:
Hopital Lariboisière

Brief Summary:
Aging is an independent risk factor, without any clear explanation. The primary aim of the study is to depict the effect of aging on the coagulation fibrinolysis parameters and microparticles.

Condition or disease

Detailed Description:
Patients older than 40, without any acute disease and not receiving any antiaggregant and anticoagulant therapy will be included in the study. Blood tests will be performed for coagulation, fibrinolysis and microparticles measurement.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identifying Morphological and Biological Biomarkers of the Venous Thromboembolic Risk Risk Related to Aging
Study Start Date : October 2005
Actual Primary Completion Date : August 2006
Actual Study Completion Date : August 2006

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Stable patients without overt acute clinical event, not receiving antiplatelet or anticoagulant treatment

Inclusion Criteria:

  • age <40 2 groups : 1 : no history of VTE 2 : history of VTE

Exclusion Criteria:

  • antiaggregant or anticoagulant therapy at curative dose
  • arterial or thrombotic event in the last month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00299624

Layout table for location information
Hopital Lariboisiere
Paris, France, 75010
Hopital Lariboisière
Paris, France, 75010
Sponsors and Collaborators
Hopital Lariboisière
Layout table for investigator information
Principal Investigator: isabelle mahé, MD PhD MCU-PH

Layout table for additonal information
Responsible Party: Pr Isabelle MAHE, Hopital Lariboisière Identifier: NCT00299624     History of Changes
Other Study ID Numbers: TAPH
First Posted: March 7, 2006    Key Record Dates
Last Update Posted: September 14, 2010
Last Verified: September 2010

Keywords provided by Hopital Lariboisière:
venous thromboembolism risk,